[Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
In order to evaluate the efficacy and tolerance to Haloperidol Decanoate, 26 patients with different psychotic disorders were included in a six month's clinical study. The dose administered monthly was equivalent to twenty times the oral daily doses of neuroleptics generally used by these patients. In 92% of the cases an improvement higher than a 70% of the clinical symptoms was achieved, if comparing the baseline with final data. In no patient results inferior to those observed with oral neuroleptics were detected. Adverse reactions like parkinsonism or dyskinesia were present in some patients. However their intensity was mild to moderate, over a short period of time only.
Ellerman
L A
LA
D002986:Clinical Trials as Topic; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy*
C033563:haloperidol decanoate; D006220:Haloperidol
Estudio clínico abierto con haloperidol decanoato en pacientes con trastornos psicóticos.